Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review.

Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain.
Journal of Affective Disorders (Impact Factor: 3.71). 04/2008; 110(1-2):1-15. DOI: 10.1016/j.jad.2008.02.012
Source: PubMed

ABSTRACT The main objective of this review of the literature was to evaluate the safety and efficacy of Vagus Nerve Stimulation (VNS) in treatment-resistant depression (TRD) by means of systematic review and meta-analysis.
A systematic review of the literature was made using the major databases (Medline, Psychological Abstracts, Current Contents), beginning in January 2000 and ending in September 2007. Ninety-eight references were found, but only 18 add-on studies met the required quality criteria and were included in this review. Only one double-blind, randomized study was available and therefore a meta-analysis was not feasible.
In a majority of the preliminary open studies selected for this review, VNS was associated with a significant reduction of the depressive symptoms (primary outcome: Hamilton Depression Rating Scale, HDRS) in the short and long term. Unfortunately, the only double-blind study gave rather inconclusive results. Generally, VNS is reported to be a safe and feasible procedure, despite its invasive nature.
VNS seems to be an interesting new approach to treating TRD. However, despite the promising results reported mainly in open studies, further clinical trials are needed to confirm its efficacy in major depression. Moreover, studies on its mechanism of action and cost-effectiveness are also required to better understand and develop VNS therapy for affective disorder.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Exposure-based therapies, medications, or device-based brain stimulation techniques are now current therapies that are offered to individuals suffering from post-traumatic stress disorder. Despite the refinement and evolution of these different interventions, some individuals still remain symptomatic. Neuroscience-based knowledge suggests that fear conditioning and extinction paradigms are a good experimental model to mimic exposure-based therapy. The field has recently put considerable efforts to test various pharmacological compounds that could be used as adjuncts to therapy by increasing the consolidation of the memory that is being formed during the therapy session. In this review, we propose to use device-based brain stimulation techniques to augment the efficacy of exposure-based therapy in individuals suffering from PTSD. Rather than using it as a therapeutic tool on its own, we describe how device-based brain stimulation techniques could be used to target regions known to be dysregulated when learning and/or recalling safety memory traces in PTSD patients.
    06/2015; 2(2). DOI:10.1007/s40473-015-0042-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple brain structural abnormalities have been reported in schizophrenia and major depressive disorder. A majority of disease-affected brain regions act as relay nodes within neural networks, which are known to be impaired in neuropsychiatric diseases. One of these regions is the claustrum, which has the highest connectivity in the human brain by regional volume. Its possible involvement in disturbed connectivity is yet incompletely explored, however. The present study aimed at searching for possible structural deviations of the claustrum in neuropsychiatric disorders. We found bilaterally reduced claustral volumes both in schizophrenia and in major depressive disorder. These structural impairments may have different, disease-related consequences: In patients with schizophrenia, they may contribute to sensory processing impairments, and in patients with major depressive disorder to disturbances in salience.
    European Archives of Psychiatry and Clinical Neuroscience 03/2015; DOI:10.1007/s00406-015-0597-x · 3.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract These guidelines for the treatment of unipolar depressive disorders systematically review available evidence pertaining to the biological treatment of patients with major depression and produce a series of practice recommendations that are clinically and scientifi cally meaningful based on the available evidence. These guidelines are intended for use by all physicians assessing and treating patients with these conditions. The relevant data have been extracted primarily from various treatment guidelines and panels for depressive disorders, as well as from meta-analyses/reviews on the effi cacy of antidepressant medications and other biological treatment interventions identifi ed by a search of the MEDLINE database and Cochrane Library. The identifi ed literature was evaluated with respect to the strength of evidence for its effi cacy and was then categorized into fi ve levels of evidence (CE A-F) and fi ve levels of recommendation grades (RG 1 – 5). This second part of the WFSBP guidelines on depressive disorders covers the management of the maintenance phase treatment, and is primarily concerned with the biological treatment (including pharmacological and hormonal medications, electroconvulsive therapy and other brain stimulation treatments) of adults and also, albeit to a lesser extent, children, adolescents and older adults.
    The World Journal of Biological Psychiatry 02/2015; 16(2). DOI:10.3109/15622975.2014.1001786 · 4.23 Impact Factor